Please sign in to follow a disease.
Biologic showdown: which IBD drug works best after a year?
NCT ID NCT07495644
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 95 adults with moderate-to-severe Crohn's disease or ulcerative colitis in Upper Egypt who are taking one of five biologic drugs: adalimumab, infliximab, ustekinumab, golimumab, or vedolizumab. After one year, researchers will measure how many patients avoid hospitalization, surgery, and steroids, and achieve endoscopic remission. The goal is to compare the effectiveness of these treatments in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab (biologic drugs)
- What this could lead to
- If successful, this could show which biologic works best for controlling IBD over a year, helping doctors choose more effective treatments.
- What could go wrong
- This is a small, early-stage study (95 people) in one region, so results may not apply broadly. Biologics also carry risks like serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 95 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study is a retrospective, observational study involving chart reviews of patients with inflammatory bowel disease (IBD) at Luxor International Hospital.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
1. Inclusion Criteria: 1) Age ≥ 18 years; 2) Patients with moderate-to-severe ulcerative colitis, defined as a clinical Mayo score \>6 with an endoscopic score of 2-3 3) Patients with moderate-to-severe Crohn's disease, defined as a Crohn's Disease Activity Index (CDAI) \>220 with a Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥7 4) Patients receiving adalimumab, infliximab, ustekinumab, or vedolizumab; 5) Patients who had been on the current biologic therapy for between 6 weeks and 12 months; and 6) Biologic-naïve patients (no prior biologic therapy). Patients who did not continue their treatment for 12 months due to primary or secondary treatment failure will be considered not to have achieved endoscopic remission. Additionally, patients who were hospitalized, received corticosteroids, or underwent surgery due to medication failure before 12 months of therapy will be considered treatment failures. 2. Exclusion Criteria: 1. Patients with prior biologic therapy (biologic-experienced); 2. Patients with incomplete outcome or therapy data; 3. Patients receiving other concomitant biologic or small-molecule therapies for other conditions, such as rheumatological diseases; 4. Pregnant patients; 5. Patients with intermittent suspension of therapy during the 12-month period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Inflamatory bowel disease (Crohn'S and ulcerative colitis) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.